Observation Of The Clinical Effect Of Dapagliflozin Combined With Insulin In The Treatment Of Type 2 Diabetes With Hyperuricemia

Objectives To observe the clinical efficacy of dapagliflozin combined with insulin in the treatment of T2 DM combined with HUA,and to provide a theoretical basis for patients with T2 DM combined with HUA to choose a hypoglycemic regimen.Methods 90 patients with T2 DM combined with HUA who were hospitalized in the Department of Endocrinology,North China University of Technology Hospital from October 2018 to October 2019 were selected.The 90 patients enrolled were randomly divided into an observation group(40 cases of dapagliflozin combined with insulin)and a control group(50 cases of insulin alone).The observation group was given dapagliflozin 10 mg oral 1/day combined with insulin therapy,and insulin was adjusted according to blood glucose level.The control group was given insulin therapy,and insulin was dosed according to blood glucose level.The course of treatment was 12 weeks.Compare SUA,24-hour urine UA,Hb A1 c,FPG,2h PG,insulin dosage,body weight,SBP,DBP,TC,TG before and after treatment,and record hypoglycemia,urinary tract infection,fracture,cancer and other adverse events during treatment reaction.Results Ninety patients with T2 DM and HUA were enrolled,and 4 patients were lost to follow-up.1 There was no significant difference in baseline data between the two groups before treatment,including age,gender,smoking history,course of disease,body weight,and insulin dosage(P>0.05).2 After 12 weeks of treatment,the observation group’s 24-hour urine UA,Hb A1 c,insulin dosage,body weight,SBP,DBP improved significantly compared with the control group,and the difference between the groups was statistically significant(P<0.05).3 5 cases of mild hypoglycemia occurred in the observation group with an incidence rate of 13.51%,and 12 cases of mild hypoglycemia occurred in the control group with an incidence rate of 24.49%.There was no significant difference between the groups(P>0.05).No severe hypoglycemia occurred in either group.Conclusions Dapagliflozin combined with insulin in the treatment of patients with T2 DM and HUA can promote 24-hour urinary UA excretion,reduce insulin consumption,reduce FPG,2h PG,Hb A1 c levels,reduce body weight,and lower blood pressure.Figure0;Table 13;Reference 167...